Nexalin Technology, Inc. (NASDAQ:NXL)
| Market Cap | 4.20M-79.0% |
| Revenue (ttm) | 217.16K+24.2% |
| Net Income | -8.99M-1.6% |
| EPS | -14.40+37.7% |
| Shares Out | 733.71K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,345,020 |
| Open | 5.60 |
| Previous Close | 7.55 |
| Day's Range | 5.15 - 5.95 |
| 52-Week Range | 4.00 - 60.00 |
| Beta | 3.98 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About NXL
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
$NXL stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in NXL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NXL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NXL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
NXL Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Stock based compensation | $408.39K | 50.06% |
| Professional fees | $407.44K | 49.94% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New NXL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NXL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NXL
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $29.95K |
Estimated from each fund’s disclosed top holdings × AUM
NXL Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from NXL’s recent data — informational, not investment advice